UBE2T/FANCL-IN-1 |
| Catalog No.GC65424 |
UBE2T/FANCL-IN-1 is a potent inhibitor of UBE2T/FANCL-mediated FANCD2 monoubiquitylation that sensitizes cells to the DNA cross-linking agent, Carboplatin.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1359415-02-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
UBE2T/FANCL-IN-1 is a potent inhibitor of UBE2T/FANCL-mediated FANCD2 monoubiquitylation that sensitizes cells to the DNA cross-linking agent, Carboplatin[1].
UBE2T/FANCL-IN-1 (CU2) completely inhibits the ubiquitylation of GST-FANCLRING at 100 μM. UBE2T/FANCL-IN-1 (500 μM) reduced the level of mUb-FANCD2 in response to HU treatment. UBE2T/FANCL-IN-1 (500 μM) also reducesthe level of mUb-FANCD2 generated in response to Cisplatin (10 μM) treatment for 6, 12, and 24 hours. The combination of 250 μM UBE2T/FANCL-IN-1 with 15 μM carboplatin led to an even more pronounced decrease in cell proliferation/growth, with the cells being <50% confluent after 8 days[1].
[1]. Cornwell MJ, et al. Small-Molecule Inhibition of UBE2T/FANCL-Mediated Ubiquitylation in the Fanconi Anemia Pathway. ACS Chem Biol. 2019;14(10):2148-2154.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *